<code id='8C0B7607EE'></code><style id='8C0B7607EE'></style>
    • <acronym id='8C0B7607EE'></acronym>
      <center id='8C0B7607EE'><center id='8C0B7607EE'><tfoot id='8C0B7607EE'></tfoot></center><abbr id='8C0B7607EE'><dir id='8C0B7607EE'><tfoot id='8C0B7607EE'></tfoot><noframes id='8C0B7607EE'>

    • <optgroup id='8C0B7607EE'><strike id='8C0B7607EE'><sup id='8C0B7607EE'></sup></strike><code id='8C0B7607EE'></code></optgroup>
        1. <b id='8C0B7607EE'><label id='8C0B7607EE'><select id='8C0B7607EE'><dt id='8C0B7607EE'><span id='8C0B7607EE'></span></dt></select></label></b><u id='8C0B7607EE'></u>
          <i id='8C0B7607EE'><strike id='8C0B7607EE'><tt id='8C0B7607EE'><pre id='8C0B7607EE'></pre></tt></strike></i>

          focus

          focus

          author:explore    Page View:4
          Five people put coins in a box containing coins and cash on stage — coverage from STAT
          Adobe

          In the United States, health care costs are so out of control that medical crowdfunding has become commonplace. The idea is simple: turn your social network into a financial safety net to cover the cost of expensive treatments or long illnesses. Millions of Americans have started crowdfunding campaigns for medical bills, and tens of millions have donated to them, mostly through the undisputed sector leader, GoFundMe.

          Nora Kenworthy, a nursing and health studies professor at the University of Washington, Bothell, has spent years studying the world of crowdfunding for health care — along with the way it ends up amplifying the inequities that already dictate who goes into medical debt.

          advertisement

          In her new book, “Crowded Out: The True Costs of Crowdfunding Healthcare,” which will be released on Tuesday, she looks at what she calls the “toxicities” that drive medical crowdfunding campaigns. STAT spoke with Kenworthy about those issues, as well as the difficult moral decisions potential donors face when deciding whether to contribute. The following interview is condensed and edited for clarity.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          How to save PrEP access — and even expand it
          How to save PrEP access — and even expand it

          UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

          read more
          A new ‘biological computer' targets cancer while sparing healthy cells
          A new ‘biological computer' targets cancer while sparing healthy cells

          AdobeTheholygrailofcancerdrugtargetsisakintoaunicornhorn:amarkerthatonlycancercellshave,clearlydisti

          read more
          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more

          European regulators consider appeal over Amylyx ALS drug

          PauloAmorim/VWPicsviaAPImagesLONDON—Thisweek,EuropeanregulatorsareconsideringanappealfromAmylyxPharm